anti-myeloma

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 IgG4 monoclonal antibody that exhibits antitumor activity by blocking CD47 and binding primarily to the N-terminal pyroglutamate of CD47. It can be used in combination with other compounds for the treatment of recurrent myeloma.

Lucatumumab (HCD122) is a fully human anti-CD40 monoclonal antibody with antitumor activity that blocks the interaction of CD40L with CD40 and inhibits the CD40 CD40L-mediated signaling pathway for the study of chronic lymphocytic leukemia (CLL) and multiple myeloma.

Daratumumab is a human monoclonal antibody that targets CD38 a cell surface protein that is overexpressed on multiple myeloma MM) cells.

Modakafusp alfa (TAK-573) is a humanized anti-CD38 IgG4 monoclonal antibody fused with 2 attenuated IFNα2b molecules, being researched for potential use in treating multiple myeloma [1].

XmAb 5592 is a Fc-engineered and humanized anti-HM1.24 antibody with anti-tumor activity, used in the study of multiple myeloma.

Cetrelimab (JNJ 63723283) is a humanized anti-PD-1 monoclonal antibody that dose-dependently increases T cell-mediated cytokine production and stimulates cytokine expression. It is used in multiple myeloma and bladder cancer research.

Elotuzumab(HuLuc 63) is a monoclonal antibody that targets the SLAMF7 receptor.Elotuzumab is a compound that directly activates NK cells and induces antibody-dependent cytotoxicity, and can be used in combination with lenalidomide and dexamethasone (Ld) to treat multiple myeloma.

Vorsetuzumab mafodotin, a humanized anti-CD70 monoclonal antibody, conjugates with monomethyl auristatin F (MMAF) through Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. This affinity allows targeting of various solid tumors and cancers such as renal cell carcinoma, pancreatic, ovarian, and lung cancers, alongside multiple myeloma and several forms of non-Hodgkin lymphoma, all of which express CD70.

Ulocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), and multiple myeloma transplantation models.Ulocplumab inhibits the migration of chronic lymphocytic leukemia (CLL) cells under CXCR4 activation, induces apoptosis, and inhibits the growth and migration of cancer cells. Ulocplumab inhibits CXCL12-mediated chronic lymphocytic leukemia (CLL) cell migration in response to CXCR4 activation and induces apoptosis.)